| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
6,396 |
4,731 |
$537K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,071 |
1,974 |
$210K |
| 99215 |
Prolong outpt/office vis |
2,157 |
1,512 |
$161K |
| S9088 |
Services provided in an urgent care center (list in addition to code for service) |
5,436 |
4,298 |
$100K |
| 99205 |
Prolong outpt/office vis |
657 |
633 |
$56K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
907 |
809 |
$52K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
612 |
592 |
$42K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
992 |
904 |
$30K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
566 |
537 |
$25K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
219 |
211 |
$15K |
| 99417 |
Prolong home eval add 15m |
792 |
680 |
$14K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
105 |
94 |
$14K |
| 99401 |
|
688 |
492 |
$13K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
172 |
164 |
$12K |
| 87634 |
|
189 |
178 |
$10K |
| 87632 |
|
99 |
88 |
$7K |
| 87581 |
|
189 |
177 |
$5K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
190 |
177 |
$5K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
21 |
18 |
$4K |
| 87541 |
|
122 |
115 |
$3K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
133 |
129 |
$3K |
| 87641 |
|
119 |
112 |
$3K |
| 87498 |
|
119 |
113 |
$3K |
| 87486 |
|
113 |
106 |
$3K |
| 87496 |
|
108 |
101 |
$3K |
| 87500 |
|
105 |
100 |
$3K |
| 87532 |
|
103 |
96 |
$3K |
| 87640 |
|
67 |
64 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
389 |
270 |
$885.71 |
| 80306 |
|
80 |
55 |
$808.89 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
72 |
70 |
$753.54 |
| 87276 |
|
40 |
40 |
$435.77 |
| 86328 |
|
13 |
13 |
$391.20 |
| 87275 |
|
41 |
41 |
$334.96 |
| 81000 |
|
45 |
43 |
$120.69 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
13 |
12 |
$117.74 |
| 81003 |
|
27 |
24 |
$64.71 |
| 99443 |
|
15 |
15 |
$0.12 |